Syngene International Ltd (SYNGENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Syngene International Ltd (SYNGENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8037
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and manufacturing organisation. The organisation offers research, development and manufacturing programs. It provides discovery chemistry, discovery biology, large molecule development, safety assessment, chemical development, formulation development, stability studies, polymer research, integrated discovery and development, clinical development, bioinformatics, antibody drug conjugates and oligonucleotide synthasis services. Syngene’s discovert biology includes molecular biology, protein sciences, cell line development and analysis, antibody generation, screening and assay f biology, ADME and DMPK, in vivo pharmacology, and genomics and translation biology. The organisation serves pharmaceutical and biotech, agrochemical, nutrition, animal health and speciality and performance chemical industries. It works in partnership with global pharmaceutical and biotechnology companies. Syngene is headquartered in Bangalore, Karnataka, India.

Syngene International Ltd (SYNGENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngene International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syngene International Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Syngene May Raise Over USD50 Million in Venture Financing 10
Private Equity 11
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 11
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 13
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 14
Partnerships 16
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 16
Syngene International Enters into Agreement with Zumutor Biologics 17
Saniona Enters into Agreement with Syngene 18
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 19
Abbott India Enters Into Joint Venture Agreement With Syngene International 20
Equity Offering 21
Syngene International Raises up to USD86 Million in IPO 21
Syngene International Ltd – Key Competitors 23
Syngene International Ltd – Key Employees 24
Syngene International Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Apr 25, 2018: Syngene International Q4 net rises 8% to Rs 84 crore 26
Jan 23, 2018: Syngene Reports Revenue of ONR3.99 Billion in Q3 Fiscal 2018 27
Jul 27, 2017: Syngene Q1 FY18 Revenue up 6% to Rs. 308 Cr 28
Apr 27, 2017: Syngene Delivered 14% Revenue Growth in FY17 30
Jan 24, 2017: Syngene Q3 Revenue up by 23% 32
Corporate Communications 33
Apr 27, 2017: Syngene International Appointment of Mr. Jonathan Hunt as Whole Time Director and Mr. Peter Bains, Non-Executive Director stepped down from the Board 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Syngene International Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngene International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngene International Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syngene May Raise Over USD50 Million in Venture Financing 10
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 11
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 13
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 14
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 16
Syngene International Enters into Agreement with Zumutor Biologics 17
Saniona Enters into Agreement with Syngene 18
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 19
Abbott India Enters Into Joint Venture Agreement With Syngene International 20
Syngene International Raises up to USD86 Million in IPO 21
Syngene International Ltd, Key Competitors 23
Syngene International Ltd, Key Employees 24
Syngene International Ltd, Other Locations 25
Syngene International Ltd, Subsidiaries 25
Syngene International Ltd, Joint Venture 25

List of Figures
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngene International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Syngene International Ltd (SYNGENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fulcrum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a biotechnology company which focuses on the discovery and development of small molecule therapies to unlock the gene control. Its pipeline portfolio includes Fragile X syndrome (FXS) and facioscapulohumeral muscular dystrophy (FSHD). Fulcru …
  • Qenos Pty Ltd:企業の戦略的SWOT分析
    Qenos Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Continental Resources Inc (Continental Resources) is an oil and gas company involved in the distribution of fuel and related products and services. The company offerings include supply fulf …
  • Pan Malaysia Holdings Berhad
    Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Croma-Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Croma-Pharma GmbH (Croma Pharma) is a pharmaceutical company that offers development and commercialization of drugs in the field of aesthetic dermatology. The company’s products include princess skincare, princess injectables, and princess lift products. Its princess skincare products compri …
  • HSBC Finance Corporation:企業の戦略・SWOT・財務情報
    HSBC Finance Corporation - Strategy, SWOT and Corporate Finance Report Summary HSBC Finance Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sartorius Stedim Biotech SA (DIM):企業の財務・戦略的SWOT分析
    Sartorius Stedim Biotech SA (DIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • The Yomiuri Shimbun:企業の戦略的SWOT分析
    The Yomiuri Shimbun - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Crown Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crown Bioscience Inc (Crown Bioscience) is a pharmaceutical company that provides drug discovery and development services. The company offers in vivo and in vitro research reagents. It offers preclinical contract research services in areas of oncology and metabolic disease. Crown Bioscience’ …
  • TenneT Holding BV:電力:M&Aディール及び事業提携情報
    Summary TenneT Holding BV (TenneT), owned by the Ministry of Finance of The State of the Netherlands, is an electricity transmission system operator. The company offers electricity transmission and system services. It constructs and maintains high voltage grid to transmit electricity from the produc …
  • Carnarvon Petroleum Ltd (CVN):企業の財務・戦略的SWOT分析
    Summary Carnarvon Petroleum Ltd (Carnarvon Petroleum) is an oil and gas company that acquires, explores, and develops oil and gas properties. The company's projects comprise Cerberus and the Phoenix project. It has assets in Barrow sub-basin, Perth basin, and Roebuck basin. Carnarvon Petroleum's Pho …
  • Sekisui Diagnostics LLC:製品パイプライン分析
    Summary Sekisui Diagnostics LLC (Sekisui Diagnostics), a subsidiary of Sekisui Chemical Co Ltd is a medical device company that develops, manufactures and supplies clinical diagnostic and research products. The company’s products include coagulation, clinical chemistry, virotech products, OSOM rapid …
  • Aveng Ltd (AEG):企業の財務・戦略的SWOT分析
    Aveng Ltd (AEG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PT Bio Farma:製薬・医療:M&Aディール及び事業提携情報
    Summary PT Bio Farma (Bio Farma) is a manufacturer and supplier of vaccines, sera, and biological and diagnostics products. The company offers products such as DTP-hep B vaccine, DTP vaccine, DT vaccine, TT vaccine, polio vaccine, measles vaccine and BCG vaccine. It also offers biott vaccine for the …
  • Tethys Petroleum Ltd (TPL.H):石油・ガス:M&Aディール及び事業提携情報
    Summary Tethys Petroleum Ltd (Tethys) is an independent oil and gas exploration and production company. It focuses on projects in Central Asia and the Caspian Region. The company has a portfolio of assets, including existing oil and gas production, frontier high impact exploration and unconventional …
  • RELX Group plc:企業の戦略・SWOT・財務情報
    RELX Group plc - Strategy, SWOT and Corporate Finance Report Summary RELX Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Plant Bioscience Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Plant Bioscience Ltd (PBL) is a technology management company that offers services in plant, food and microbial science. The company provides intellectual property management, patent advisory, licensing and technology transfer services. It offers patient consultation and management services, …
  • Dubai Electricity and Water Authority:電力:M&Aディール及び事業提携情報
    Summary Dubai Electricity and Water Authority (DEWA) is an electricity and water utility. It generates, transmits and distributes electricity; and desalinates water. The authority produces electricity using gas and steam turbines, and solar PV plants. DEWA’s plants include Jebel Ali Station D, E and …
  • Horiba Ltd (6856):企業の財務・戦略的SWOT分析
    Summary Horiba Ltd (Horiba) is a manufacturer of precision instruments and systems. The company's product portfolio includes automotive mechatronics, emission measurement systems, test systems, in vitro diagnostic systems, gas and oxygen analyzers, monitoring devices, industrial conductivity meters, …
  • Credit Andorra SA:企業の戦略・SWOT・財務分析
    Credit Andorra SA - Strategy, SWOT and Corporate Finance Report Summary Credit Andorra SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆